AstraZeneca scraps plan to expand vaccine plant in the UK in blow to government

Associated Press Finance
01 Feb

LONDON (AP) — Pharmaceutical company AstraZeneca on Friday cancelled a planned 450 million-pound ($560 million) investment in a vaccine manufacturing plant in northwest England, blaming the new Labour government for diluting the financial support that had been offered by the previous Conservative administration.

In a blow to Treasury chief Rachel Reeves at the end of a week when she trumpeted the government's plans to bolster British economic growth and make the country more attractive to international investors, AstraZeneca said it will no longer expand its facility in Speke, near Liverpool.

“Several factors have influenced this decision including the timing and reduction of the final offer compared to the previous government’s proposal," a company spokesperson said.

The existing facility will continue to operate and no jobs are at risk.

The government said a “change in the make-up of the investment” proposed by AstraZeneca, which is headquartered in Cambridge, England, had led to a change in the grant it was willing to offer.

Details of what had changed were not immediately available.

The previous government said the investment would have given the U.K.’s life sciences sector a boost as well as improving public health protection and pandemic preparedness.

AstraZeneca became particularly prominent during the coronavirus pandemic, when it partnered with Oxford University to create one of the vaccines.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10